Prognostic significance of L1CAM in ovarian cancer and its role in constitutive NF-κB activation

Annals of Oncology

Volumn 23, Issue 7, 2012, Pages 1795-1802

  Bondong, S ^a   Kiefel, H ^a   Hielscher, T ^a   Zeimet, A G ^b   Zeillinger, R ^c   Pils, D ^c   Schuster, E ^c   Castillo Tong, D C ^c   Cadron, I ^d   Vergote, I ^d   Braicu, I ^e   Sehouli, J ^e   Mahner, S ^f   Fogel, M ^g   Altevogt, P ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^g KAPLAN MEDICAL CENTER   (Israel)

Author keywords

CD171; Cell adhesion; Chemoresistance; IL 1 ; Serous ovarian cancer; Soluble L1CAM

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN KAPPA CHAIN; INTERLEUKIN 1BETA; NERVE CELL ADHESION MOLECULE L1; TUMOR MARKER;

ADULT; AGED; ARTICLE; ASCITES FLUID; B LYMPHOCYTE ACTIVATION; CANCER CELL CULTURE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURGERY; CANCER SURVIVAL; CELL LYSATE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVARY CARCINOMA; PHENOTYPE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL RATE; SURVIVAL TIME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASCITIC FLUID; CARCINOMA; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTERLEUKIN-1BETA; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEURAL CELL ADHESION MOLECULE L1; NF-KAPPA B; OVARIAN NEOPLASMS; PHENOTYPE; PROGNOSIS; YOUNG ADULT;

EID: 84864315091     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr568     Document Type: Article

References (46)

1. Colombo N, Van Gorp T, Parma G et al. Ovarian cancer. Crit Rev Oncol Hematol 2006; 60: 159-179.
2. Shih Ie M, Kurman RJ. Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges. Clin Cancer Res 2005; 11: 7273-7279.
3. Shih Ie M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004; 164: 1511-1518.
4. Jemal A, Tiwari RC, Murray T et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54: 8-29.
5. Stuart GC. First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer. Gynecol Oncol 2003; 90: S8-S15.
6. Moos M, Tacke R, Scherer H et al. Neural adhesion molecule L1 as a member of the immunoglobulin superfamily with binding domains similar to fibronectin. Nature 1988; 334: 701-703.
7. Schachner M Neural recognition molecules and synaptic plasticity. Curr Opin Cell Biol 1997; 9: 627-634.
8. Brummendorf T, Kenwrick S, Rathjen FG. Neural cell recognition molecule L1: from cell biology to human hereditary brain malformations. Curr Opin Neurobiol 1998; 8: 87-97.
9. Maness PF, Schachner M Neural recognition molecules of the immunoglobulin superfamily: signaling transducers of axon guidance and neuronal migration. Nat Neurosci 2007; 10: 19-26.
10. Raveh S, Gavert N, Ben-Ze'ev A L1 cell adhesion molecule (L1CAM) in invasive tumors. Cancer Lett 2009; 282: 137-145.
11. Schafer MK, Altevogt P L1CAM malfunction in the nervous system and human carcinomas. Cell Mol Life Sci 2010; 67: 2425-2437.
12. Fogel M, Gutwein P, Mechtersheimer S et al. L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas. Lancet 2003; 362: 869-875.
13. Zecchini S, Bianchi M, Colombo N et al. The differential role of L1 in ovarian carcinoma and normal ovarian surface epithelium. Cancer Res 2008; 68: 1110-1118.
14. Huszar M, Pfeifer M, Schirmer U et al. Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas. J Pathol 2010; 220: 551-561.
15. Daponte A, Kostopoulou E, Kollia P et al. L1 (CAM) (CD171) in ovarian serous neoplasms. Eur J Gynaecol Oncol 2008; 29: 26-30.
16. Beer S, Oleszewski M, Gutwein P et al. Metalloproteinase-mediated release of the ectodomain of L1 adhesion molecule. J Cell Sci 1999; 112(Pt 16): 2667-2675.
17. Gutwein P, Mechtersheimer S, Riedle S et al. ADAM10-mediated cleavage of L1 adhesion molecule at the cell surface and in released membrane vesicles. FASEB J 2003; 17: 292-294.
18. Mechtersheimer S, Gutwein P, Agmon-Levin N et al. Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine binding to integrins. J Cell Biol 2001; 155: 661-673.
19. Stoeck A, Gast D, Sanderson MP et al. L1-CAM in a membrane-bound or soluble form augments protection from apoptosis in ovarian carcinoma cells. Gynecol Oncol 2007; 104: 461-469.
20. Grivennikov SI, Greten FR, Karin M Immunity, inflammation, and cancer. Cell 2010; 140: 883-899.
21. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002; 2: 301-310.
22. Mantovani A, Allavena P, Sica A, Balkwill F Cancer-related inflammation. Nature 2008; 454: 436-444.
23. Li N, Grivennikov SI, Karin M The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment. Cancer Cell 2011; 19: 429-431.
24. Darb-Esfahani S, Sinn BV, Weichert W et al. Expression of classical NF-kappaB pathway effectors in human ovarian carcinoma. Histopathology 2010; 56: 727-739.
25. Schauer IG, Sood AK, Mok S, Liu J Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer. Neoplasia 2011; 13: 393-405.
26. Kiefel H, Bondong S, Erbe-Hoffmann N et al. L1CAM-integrin interaction induces constitutive NF-kappaB activation in pancreatic adenocarcinoma cells by enhancing IL-1beta expression. Oncogene 2010; 29: 4766-4778.
27. Gavert N, Ben-Shmuel A, Lemmon V et al. Nuclear factor-kappaB signaling and ezrin are essential for L1-mediated metastasis of colon cancer cells. J Cell Sci 2010; 123: 2135-2143.
28. Kiefel H, Pfeifer M, Bondong S et al. Linking L1CAM-mediated signaling to NF-κB activation. Trends Mol Med 2011; 17: 178-187.
29. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
30. Rustin GJ. Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol 2003; 21: 187s-193s.
31. Huszar M, Moldenhauer G, Gschwend V et al. Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy. Hum Pathol 2006; 37: 1000-1008.
32. Silletti S, Yebra M, Perez B et al. Extracellular signal-regulated kinase (ERK)-dependent gene expression contributes to L1 cell adhesion molecule-dependent motility and invasion. J Biol Chem 2004; 279: 28880-28888.
33. Thelen K, Kedar V, Panicker AK et al. The neural cell adhesion molecule L1 potentiates integrin-dependent cell migration to extracellular matrix proteins. J Neurosci 2002; 22: 4918-4931.
34. Gavert N, Conacci-Sorrell M, Gast D et al. L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J Cell Biol 2005; 168: 633-642.
35. Meier F, Busch S, Gast D et al. The adhesion molecule L1 (CD171) promotes melanoma progression. Int J Cancer 2006; 119: 549-555.
36. Gast D, Riedle S, Issa Y et al. The cytoplasmic part of L1-CAM controls growth and gene expression in human tumors that is reversed by therapeutic antibodies. Oncogene 2008; 27: 1281-1289.
37. Arlt MJ, Novak-Hofer I, Gast D et al. Efficient inhibition of intra-peritoneal tumor growth and dissemination of human ovarian carcinoma cells in nude mice by anti-L1-cell adhesion molecule monoclonal antibody treatment. Cancer Res 2006; 66: 936-943.
38. Maretzky T, Schulte M, Ludwig A et al. L1 is sequentially processed by two differently activated metalloproteases and presenilin/gamma-secretase and regulates neural cell adhesion, cell migration, and neurite outgrowth. Mol Cell Biol 2005; 25: 9040-9053.
39. Stoeck A, Keller S, Riedle S et al. A role for exosomes in the constitutive and stimulus-induced ectodomain cleavage of L1 and CD44. Biochem J 2006; 393: 609-618.
40. Oleszewski M, Beer S, Katich S et al. Integrin and neurocan binding to L1 involves distinct Ig domains. J Biol Chem 1999; 274: 24602-24610.
41. Friedli A, Fischer E, Novak-Hofer I et al. The soluble form of the cancerassociated L1 cell adhesion molecule is a pro-angiogenic factor. Int J Biochem Cell Biol 2009; 41: 1572-1580.
42. Strekalova H, Buhmann C, Kleene R et al. Elevated levels of neural recognition molecule L1 in the cerebrospinal fluid of patients with Alzheimer disease and other dementia syndromes. Neurobiol Aging 2006; 27: 1-9.
43. Zander H, Rawnaq T, von Wedemeyer M et al. Circulating levels of cell adhesion molecule L1 as a prognostic marker in gastrointestinal stromal tumor patients. BMC Cancer 2011; 11(189): 181-187.
44. Reidy M, Zihlmann P, Hubbell JA, Hall H Activation of cell-survival transcription factor NFkappaB in L1Ig6-stimulated endothelial cells. J Biomed Mater Res A 2006; 77: 542-550.
45. Gutwein P, Stoeck A, Riedle S et al. Cleavage of L1 in exosomes and apoptotic membrane vesicles released from ovarian carcinoma cells. Clin Cancer Res 2005; 11: 2492-2501.
46. Sebens Muerkoster S, Werbing V, Sipos B et al. Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells. Oncogene 2007; 26: 2759-2768.